Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ardelyx Inc. ARDX

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:ARDX)

Fundamentals Snapshot (NDAQ:ARDX)

Current News (NDAQ:ARDX)

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

PR Newswire 9 days ago

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire November 16, 2022

Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire November 16, 2022

National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels

PR Newswire November 4, 2022

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights

PR Newswire November 3, 2022

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire November 3, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire November 2, 2022

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

PR Newswire October 31, 2022

Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022

PR Newswire October 27, 2022

Bullboard Posts (NDAQ:ARDX)

ARDX ...... Halted yesterday a.m and resumed AH

Closed up 82 cents in yesterdays After Hours trading and is cintinuing this a.m in the Pre Market open. News yesterday........ Ardelyx...
Iseneschal - November 17, 2022

IS IT THE END OF THE ROAD FOR ARDELYX INC?

$ARDX Clinical-Stage companies offer an exciting investment opportunity with massive upside potential.  However, even the...
AviseAnalytics - October 8, 2021

4 BIOTECH STOCKS FACING FDA REJECTION!

4 BIOTECH STOCKS FACING FDA REJECTION! Is it a full stop or a pause to their journey? SESN FGEN SPPI ARDX Read More: https://www...
AviseAnalytics - August 24, 2021

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

added more of this one

averaging down my costs,so glta.
coolfooldumbguy - September 13, 2019

it's a buy today for me

got it at $5.99 per share,it should be a double for me,it was rated for a $12 per share target price, but please DYODDD.
coolfooldumbguy - September 12, 2019